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Agaricus blazei Murrill (ABM) popularly known as ‘Cogumelo do Sol’ in Brazil, or
‘Himematsutake’ in Japan, is a mushroom native to Brazil, and widely cultivated in Japan
for its medicinal uses, so it is now considered as one of the most important edible and culinary-
medicinal biotechnological species. It was traditionally used to treat many common diseases like
atherosclerosis, hepatitis, hyperlipidemia, diabetes, dermatitis and cancer. In vitro and in vivo
ABM has shown immunomodulatory and antimutagenic properties, although the biological
pathways and chemical substances involved in its pharmacological activities are still not clear.
The polysaccharides phytocomplex is thought to be responsible for its immunostimulant and
antitumor properties, probably through an opsonizing biochemical pathway. Clinical studies are
positive confirmations, but we are still at the beginning, and there are perplexing concerns
especially relative to the content of agaritine. Argantine is a well-known carcinogenic and toxic
substance in animals, that must be completely and fully evaluated.
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Introduction
Mushrooms and primarily basidiomycetous fungi are a
popular and valuable food, low in calories and high in
minerals, essential amino acids, vitamins and fibers (1);
some of them produce substances having potential
medical effects, and are called medicinal mushrooms.
Agaricus blazei Murrill (ABM) is known in Brazil
as Cogumelo do sol or medicinel, in Japan as
Himematsutake, Agarikusutake or Kawarihiratake and in
China as Ji Song Rong. It was brought to Japan due to
alleged health effects and is widely used today in Oriental
countries both as an edible mushroom, considered a
functional food, and as natural therapy in the form of a
medicinal extract mostly for prevention and treatment of
cancer. In accordance with Brazilian tradition, it would
be useful against a variety of diseases like diabetes,
atherosclerosis, hepatitis, hypercholesterolemia, heart
disease and so on. In Japan, researchers demonstrated
immunostimulant and anticancer effects of ABM extracts
experimentally, and due to the improving consumption of
this mushroom in recent years, a considerable effort
investigated the putative effects with interesting, but
still insufficient clinical studies. Experimental studies
increased commercial interest for ABM because of
many requests as popular remedy especially in Japan,
stimulating not only the production, but also the
registration of new names and brands with new popular
names. This makes it difficult for the public to identify
pure ABM strains.
History and Ethnopharmacology
Agaricus blazei Murrill is a mushroom originally native
to a small village, name Piedade, in the highland areas
of Atlantic forest, near Tauape, in the province of
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properly cited.Sao Paolo, Brazil. It was discovered in 1960 by Takatoshi
Furumoto a grower and researcher who sent it to Japan
in 1965 for investigation. It was identified as ABM by
the Belgian botanist Heinemann in 1967 (2). Later it was
given the common name of Himematsutake in Japan,
while in Brazil it was named Cogumelo Piedade.
The mushroom is traditionally believed to fight physical
and emotional stress, stimulate immune system, improve
the quality of life in diabetics, reduce cholesterol, prevent
osteoporosis and peptic ulcer, treat circulatory and
digestive problems and fight cancer (2). All traditional
and not-proved beliefs, as often happens, are intention-
ally used and publicized on the web and mass media for
commercial purposes often without any real scientifically
demonstrated clinical benefit for patients (3). Over the
last decade, the mushroom has been studied as a novel
functional food in Japan, Korea, China and Taiwan. The
fruiting bodies are still quite expensive to grow, so a
relatively cheap and stable source for commercial purpose
is still sought. Medicinal mushrooms have an established
history of use in traditional oriental therapies: histori-
cally, hot-water soluble fractions from medicinal mush-
room were used as medicine in the Far East from where
this knowledge and practice seem to have been origi-
nated. The first historical description about the use of
mushroom of Agaricus genus for medicinal purposes is
probably described by Byzantine medical treatises in the
Mediterranean area, from the 4th century AD to the 15th
century AD by Orivasios and Apuleius for treating
malignant ulcers of the larynx (4).
Botanics
Agaricus L.: Fr. Emend Karst. is the type genus of the
family Agariaceae in the order Agariales (5), and is
generally described as having small to large fruit bodies
with white, yellow or brown pileus; free lamellae that are
pallid or pinkish when young, later becoming chocolate-
brown; and also dark-brown, smooth basidiospores (6).
This highly diverse genus was divided into three
subgenera by Heinemann (7): Agaricus, Conioagaricus
and Lanagaricus. In this subdivision, the subgenus
Agaricus contains the most typical species.
Agaricus spp. are saprophytes widely distributed over
geographical areas from the tropics to the boreal regions,
inhabitating a variety of habitats from alpine meadows,
to salty and sandy seashores, to deciduous and conifer
woodlands (6) The most economically important species
is A. bisporus Imbach that is the most widely cultivated
edible mushroom, accounting for 32% of the more than
million metric tons of mushrooms produced worldwide in
1997 (8). ABM (Fig. 1) is a large Agaricus species with a
brownish-gold cap (7–2cm broad), convex, fleshy, the
stem short and hard, with chocolate brown basidiospores
(5 4mm) and is closely related to A. subrufescens (9,10).
The mushroom grows with a stalk length and a cap
diameter that are about equal (campestroid type). As a
litter-decomposing fungus, it naturally grows well in soils
rich in lignicolous debris, in mixed woods, along forest
edges and manures. Nowadays main cultivation centers
are established in Japan, China and Brazil, where the
fungus is cultured in enriched composts or pasteurized
substrates supplemented with nitrogenous additives (10).
New data indicate that the medicinal mushroom from
Brazil and Japan could be biologically and phylogeneti-
cally the same species as A. subrufescens Peck from North
America, although a search on the web and a review of
diverse commercial product literature indicate that
association of the name ABM with the Brazilian mush-
room is attributed to P. Heinemann (11). So there
would be an interfertility between North American
A. subrufescens and the ‘medicinal Agaricus’; the presence
in hybrids of genetic materials from two progenitors and
novel phenotypes indicate that members of these geo-
graphically distant mushroom populations might consti-
tute a single ‘biological species’ (11). This could be
confirmed by the paper of Colauto (12) showing little
genetic variability among commercialized strains based
on results of RAPD analysis data of 20 primers from
fungi cultivated in malt-agar medium for DNA extrac-
tion. The paper showed that some commercialized
A. blazei spawns in Brazil have identical genotypes,
and are probably clones having the same origin, which
could be Japan (12). Nevertheless, recently Wasser has
Figure 1. Agaricus blazei Murill mushroom.
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mushroom concluding that ABM differs from A. blazei
ss. Heinemann in (i) size, shape of fruit bodies and pileal
surface; (ii) type of pileal covering; (iii) presence of
cheilocystidia; and (iv) spore size. That is, North
American endemic species A. blazei ss. Murrill and the
widely cultivated medicinal A. blazei ss. Heinemann
would be two different species; and A. blazei ss.
Heinemann should be considered a new species:
A. brasiliensis (13,14). This problem is probably to be
considered still open until an official international
consensus statement will end this botanical dispute.
Phytochemical Constituents
Chemical Composition
In general, the gross composition of mushrooms is water
(90%), protein (2–40%), fat (2–8%), carbohydrates
(1–55%), fiber (3–32%) and ash (8–10%) (ash is mainly
composed of salts, metals and so forth). Active metabo-
lites can be isolated from fruiting bodies, pure culture
mycelia and culture filtrate, and nowadays many attempts
are being made to obtain active metabolites from mycelia
through submerged fermentation culture to obtain
cheaper preparations. Kawagishi was the first to separate
an active anticancer compounds purified from the sodium
hydroxide extract of the fruit body of ABM (15). The
author detected polysaccharides with apparent antitumor
activity, the major fraction being FIII-2-b, which
comprised a protein complex composed of 43.4% protein
and 50.2% carbohydrates (15). The FIII-2-b fraction
contained simple (1-6)-b-D-glucopyranosyl chains. A
significant contribution to the anticancer activity of the
protein moiety of FIII-2-b was also speculated following
the complete loss of antitumor activity after formolysis.
ABM fruiting bodies in different stages of maturity
contain a-glucans and b-glucans: the yield and structural
diversity of glucans increase as the fruiting bodies mature;
so the time of the harvest and conservation is of great
importance, to obtain the best extract, data that almost
invariably are not reported in scientific articles.
The a and b-glucan Structure
ABM glucans are side branches of a (1-6)-b-backbone as
found by Dong and Ohno, who described that active
fraction of b-glucans of ABM fruiting bodies had a (1-6)-
b-backbone structure (or functional center) with (1-3)-b-
side branches in the ratio of 1 : 2 (16); while the linear
(1,6)-b-glucan seems to be inactive (17) (Fig. 2). The
biochemical importance of (1-3)-b-side branches has been
confirmed and has shown the enhancement of the
immunomodulatory activity of polysaccharides (18);
and Mizuno (19) reported an important antitumor
activity linked to the water-soluble (1-6)-(1-3)-b-D-
glucan. However, a significant increase of water-soluble
(1-4)-a-glucan with apparent antitumor activity occurs
during maturation (19); so probably cap-opened, more
fragile mature fruiting bodies of ABM should be selected
over immature ones for the production of nutraceuticals
because they contain the most useful glucans (20).
In addition, an a-1,6 and a-1,4 glucan complex (21)
and a glucomannan with a main chain of b-1,2-linked
D-mannopyranosyl residues have been isolated from this
mushroom and found to inhibit tumorigenesis (22).
Mechanisms of Tumorigenesis and Carcinogens
These results suggest that whole-mushroom extracts
contain compounds that may modulate tumorigenesis
and carcinogenesis at different stages and/or may act at
the same stage through different mechanisms. Responses
to such highly different polysaccharides are likely to be
mediated by different cell-surface receptors, which may
be present only on specific subsets of cells, and may
trigger distinct downstream responses. A combination of
such responses involving different cell subsets could
conceivably provide greater tumor inhibition than could
be induced by a single polysaccharide. Nevertheless,
a very important problem is the wide number of different
and only partially homogeneous ABM extracts used to
study the pharmacological activities of its constituents
representing a difficult challenge to establish the best
extract and active substances. Thus all these similar
constituents could potentially provide additive, or even
synergistic, effects in the prevention and treatment of
cancer. Moreover they could interfere with other
substances or healthy physiological functions. This has
been shown by an in vitro study in which increasing
fractionations of an ABM extract enhanced some
biological activities but abolished others (23).
Immunologic Intervention
The specific mechanisms that contribute to an enhanced
state of immunity remain partially understood. Recent
insights in two rapidly expanding fields, the cytokine-
mediated homeostasis of mature lymphocytes by cyto-
kines, such as interleukins and autoreactive T cells by
Figure 2. (1–6)-b-backbone structure (or functional center) with (1–3)-
b-side branches.
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for what might be occurring.
Recent advances in immunology have demonstrated
the importance of local interactions between antigen-
presenting cells and effector cells such as natural killer
cells and T-lymphocytes for an effective immune reaction
against tumors (24). Interferon stimulate such interac-
tions, while interleukins play a central role in the
activation of NK cells and T-lymphocytes. Interferons
were investigated as potential anticancer agents because
of their antiproliferative and cytotoxic effects, their
ability to activate specific components of the immune
system and their relatively modest toxicities. Increasing
biological evidence supports the hypothesis that
tumor-generated chemokines provide more than simply
angiogenic signals. Tumor-derived chemokines may
potentially act as inhibitors of anti-tumor immune
responses as well as autocrine growth factors for the
tumor. All these chemokines activating activities of
A. blazei Miller remain to be completely evaluated both
in animal model and in real clinical practice.
However, immunologically active glucans are (1-3)-b-D-
linked glucose polymers, which occur as a primary
component in the cell walls of bacteria and fungi or are
secreted extracellularly by various fungi, and actually
seem the most important active substance.
Studies in vitro
Biological Activities on the Immune System
The immunostimulant and immunomodulatory activity
of both mycelial and fruiting bodies of ABM using water
and ethanol extracts have been demonstrated in many
in vitro experiments, although not always the results are
concordant, but sometimes contradictory. Water extracts
of the mycelial culture and fruiting bodies such as
fractions B-4, B-5 obtained from ethanol precipitation
(respectively 44% and 50%) of fruiting bodies, markedly
induced TNF production and IL-8 of macrophages
derived from rat bone-marrow (23). Fraction B-5 induced
a significant increase in nitric oxide production, (23).
In another paper, the same group using ethanolic
fractions obtained from mycelia inhibited the occurrence
of the viral cytopathic effect induced by Western equine
encephalitis and herpes simplex (25). Other extracts
containing lignin-based derivatives have shown the
induction of TNF-g, IL-8 and nitric oxide secretion by
macrophages (26), anti-viral activity of different viruses
(27), and direct anticancer activity (28); so lignin
derivatives apparently have more different and important
pharmacological activities. While, on the contrary,
a down-regulation of IL-2, IL-4 and INF-g in human
peripheral blood mononuclear cells has also been
documented (27). A hemicellulase-treated ABM fraction
derived from mycelia composed of 63.3% carbohydrates,
30.9% proteins, 0.3% lipids and other minor components
has shown to stimulate immature dendritic cell obtained
from mice bone-marrow and up-regulate the expression
of costimulatory molecules and MHC antigen, although
did not increase the production of inflammatory
inducible cytokines (30). ABM pre-treated dendritic
cells inhibited some bacteria-mediated dendritic cells’
responses, ABM pre-treated macrophages reduced LPS-
induced NF-kB activity, while ABM-mediated dendritic
cells enhanced the Th1 response in allogenic mixed
lymphocyte reaction. These antithetical effects may
probably help to maintain immunological homeostasis,
so the question is: can they be clinically effective in
cancer patients? (30). Fine particles of ABM fruiting
body and mycelium, respectively, prepared by mechanical
disruption, activated the human complement system via
the alternative pathway in human serum, is another proof
of its activity in enhancing natural immunity in bacterial
infections (31). From these studies it is clear that the
ABM fractions act on many different biological receptors
of the immune system but can also have antithetical
pharmacological activity; so further studies are warranted
to completely identify the real importance of this mush-
room as an immunostimulant and/or immunomodulator.
Anticancer Activity
Anticancer Activity of Different Extracts
The ABM aqueous extract demonstrated no clastogenic
activity whilst to have anticlastogenic properties with a
100% reduction of chromatid and 144.4% reduction of
isochromatid breaks, is apparently really important for
cancer prevention in humans since it is usually consumed
in its natural form as tea or as food (32). Nevertheless,
we emphasize that if in the same study methanolic and
hexanic extracts were anticlastogenic, n-butanolic extract
were both anticlastogenic and clastogenic (32); and in
another article different hexane extracts of the fruiting
body in culture of mammalian cells were at different
concentrations genotoxic, cytotoxic and anticlastogenic;
so these findings clearly suggest further studies are
needed (33). Oliveira (34) studied ABM aqueous extracts,
by simultaneous and pre-incubation administration, and
demonstrated a strong protective effect based on the
cytokinesis-blockmicronucleus (CBMN) assay under both
conditions, suggesting a desmutagenic activity, and
Menoli (35) observed a protective effect against CBMN
induced by methyl methanesulfonate, when cells were
treated with an aqueous extract of ABM strains mixture;
and in the comet assay, the same authors also observed
antigenotoxic potential. Moreover, resident human per-
ipheral nucleated cells incubated in the presence of
complement-opsonized complexes of fruiting bodies
6 The medicinal mushroom Agaricus blazei Murrillinhibited the proliferation of the human thyroid carci-
noma cell line TPC-1 (31). Recently it has been shown on
human gastric epithelial AGS cells that an aqueous
extract can activate apoptosis through induction of
caspase-3 and related cell cycle arrest at the G2/M
phase (36).
Different Anticancer Activity of ABM Strains
ABM extracts have not always shown a protective effect
against cancer. Delmanto (37) using the micronuclei test
against genotoxicity induced by cyclophosphamide, found
a decrease in the frequency of micronuclei after treating
mice of mixed lineages with teas pre-treatment, but there
was no lower micronuclei frequency with the isolated
lineage AB 99/26. Luiz (38) did not find any antimuta-
genic activity in ABM aqueous extracts against methyl
methanesulfonate in V79 cells, using the CBMN and
comet assays. While using the comet assay, Guterrez (39)
found no protective effect for ABM aqueous extracts in
V79 cells, suggesting that differences in the cultivation,
storage and extracts preparation could influence the
effectiveness of preparations. In testing ABM aqueous
extracts of three different origins (Botucatu-SP,
Londrina-PR and Piedade-SP), Guterrez (39) observed
any genotoxic potential, while an antigenotoxic activity
only for ABM from Piedade-SP with pre-, post- and
simultaneous treatments, and for ABM from Londrina-
PR only following simultaneous treatment.
All these data implicate that lineages and pre-treatment
types influence the pharmacological anticancer activity
of ABM extracts and as confirmed by Manzi
and Pizzoferrato (40) beta glucans, apparently the most
important constituent, in mushrooms are distributed
variably both in the soluble and in the insoluble dietary
fraction. Luiz (41) has demonstrated that ethanol and
chloroform/methanol extracts have anticlastogenic activ-
ity, although without a dose-response correlation, and
the author suggests that because of a deficient repair
of CHO-xrs5 cells, an activity as modulators of DNA
replication and repair, and that probably fatty acids
contained in the extract (especially linoleic and eicosa-
pentanoic acid) could have a role in the antimutagenic
activity of the mushroom.
In vitro Studies on Cytokines Stimulation of ABM
Examination of the cytokine-inducing activity of
hemicellulase-derived mycelia extract on human peripheral
mononuclear cells have shown induced expression of IL-12,
a critical regulator of immune response against pathogens
and tumors as it is the most potent promoter of type 1
responses in CD4T cells; confirmed in the same article that
oral administration to mice showed significant higher levels
of NK cytotoxic activity of murine spleen cells (42).
Stimulation of NK-cells is obtained by higher production
of IFN-g through hydroalcoholic extracts of fruiting body
fractions, although the activity was significantly reduced
after heat treatment of 2h at 120 C in murine spleen
cell (43). In an experimental research using a 9% solution
of an aqueous ABM, extracts containing 300mgml
 1 of
b-glucans were examined to determine changes of gene
expression caused by the extract on a human monocyte
cell line, and drastic effects on gene expression were found:
genes related to immune function were selectively
up-regulated, particularly pro-inflammatory genes such as
the interleukins IL-1b and IL-8. Although most genes
induced by ABM were also induced by LPS, ABM
produced a unique profile, e.g. as to a particular increase
in mRNA for the chemokine ligands 1, 2 and 3, IL-1A,
as well as prostaglandine-endoperoxidase synthase 2
(cyclooxygenase2); and gave rise to 63% inhibition of
DNA synthesis and 30% inhibition of protein synthesis
(44) (Table 1).
ABM extracts act mainly through modulation of
the immune system activating macrophages, neutrophils
and lymphocytes (21,45,46,47) confirming the possible
anticancer activity by an enhanced immunostimulation.
About protection against atherosclerotic vascular dis-
eases, ABM has shown interesting antioxidant activity.
In one study, ethanolic extract had a remarkable
antioxidative substance effective in the auto-oxidation
of linoleic acid (48); and as confirmed by an in vitro study
through the trx1trx2 mutant method, ABM has
demonstrated to contain thermostable potent antioxidant
substances, since the extract was prepared by boiling the
mushroom in water for 120min and autoclaving (49); and
a wine produced by ABM contains 0.68% b-D-glucan and
8% alcohol showing fibrinolytic activity on artificial
bovine thrombus, that, a preventive effect on thrombosis
may pose the problem of administration in hypocoagul-
able defeated patients of more concentrated extracts (50).
On the basis of these discrepancies and the lack of
homogeneity in the type of extracts used for experiments,
it is difficult to now obtain reliable and definitive data
about anticancer activity in vitro of ABM extracts, such
as the immunological effects; so these studies are still in
their infancy and probably a better definition of active
Table 1. Chemokine-stimulated secretion
TNF-a secretion by macrophages (23)
IL-8 (23), 12 (42), 1 (44) and 2B (44),10 (44)
Nitric oxide production by macrophages (23)
Stimulation of immature dendritic cells (30)
Enhanced Th1 response (30)
Activated the human complement system via the alternative
pathway (39)
Stimulation of NK cytotoxic activity (42)
Higher production of IFN-g (43)
mRNA increase for chemokine ligand 1, 2 and 3 (44)
mRNA increase for cyclossigenase 2 (44)
mRNA increase for regulator of G-protein signaling 1 (44)
Induction of caspase 3 (36)
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cell and interactions with cell physiological processes.
Anticancer Activity of b-Glucans
Early reports showed that b-glucans functioned by
stimulating host defense mechanisms and were not toxic
for tumors, but in following years b-1,3;1,6-glucans
from fungi (e.g. mushrooms) and yeast became a new
biological entity, so-called biologic response modifiers
that function as immunostimulants against infectious
diseases and showing a possible tumoricidal activity (51).
Unlike most other natural products, purified b-1,3-glu-
cans retain their bioactivity, and this has permitted the
characterization of how b-1,3-glucans can work on a
cellular and molecular level, showing that they function
through stimulation of granulocytes (neutrophils and
eosinophils), monocytes, macrophages and NK-cells (52).
Certain data also suggested that b-glucans could promote
T cell-specific responses, perhaps, through triggering the
secretion of IFN-g, IL-6, IL-8 and IL-12 from macro-
phages, neutrophils and NK-cells, and a role for T cells
in b-glucan function was also proposed because of absent
tumoricidal activity in nude or T-cell-depleted mice (53).
Anticancer Activity and b-Glucan Conformation
Polysaccharide antitumoral activity has been evaluated
most often against allogenic sarcoma 180 in CD-I mice,
a tumor sensitive to immunomodulating compounds.
Of the polysaccharides with immunomodulating capacity,
only those which consist of a (1!3)-linked b-glucan
backbone with (l!6)-linked b-D-glucopyranosyl units as
branches produce complete inhibition of tumor growth.
(1!3)-b-glucans from fungi commonly have a tumor
inhibition percentage of 99–l00%, while other polysac-
charides exhibit l0–40% inhibition (54). Contradictory
data exist on the influence of molecular weight, degree of
branching, conformation and intermolecular associations
of b-glucans on antitumor activity and on the mecha-
nism(s) of their action (55). Most of the (1!3)-linked
b-glucans with biological response modifier activity have
been isolated from Basidiomycetes; a few with pro-
nounced antitumor activity have come from Ascomycetes
and Oomycetes (56).
Evidence suggests that the activity of these polysac-
charides is also dependent on their size, with high
molecular weight (100000–200000) fractions being most
active, while fractions from the same source with
molecular weights of 500–10000 show no activity (55).
The fact that there are polysaccharides with different
chemical structures, but all of which have immunomod-
ulating activity (56), suggests that the immune response is
in part non-specific, determined by size rather than by
chemical structure.
b-Glucan and Human Receptors
At least four receptors have subsequently been identified:
complement receptor 3, lactosylceramide, scavenger
receptors and Dectin-1. In addition to an iC3b binding
site, complement receptor 3 possesses a lectin site for
b-glucans that, in combination with iC3b, enhances
phagocytic and cytotoxic responses (57). b-glucans can
also prime the receptor for subsequent iC3b-mediated
cytotoxic responses, including the iC3b-restricted anti-
tumor activity (57). Lactosylceramide, a major glyco-
sphingolipid of polymorphonuclear leukocytes, and
selected scavenger receptors have also been identified as
receptors for b-glucans, although their role in b-glucan-
mediated responses is less clear (57).
Willment (56) has recently shown that the human
receptor is widely expressed, functions as a pattern
recognition receptor for b-glucans, and can also recognize
T-lymphocytes (57). In contrast to the mouse receptor,
the human receptor is alternatively spliced and splicing
appears to be regulated in different cell types and various
receptor isoforms generated by alternative splicing that
differ in their ability to recognize b-glucans.
Although the two predominant isoforms are both
expressed in multiple tissues they are expressed differently
in various cell types, suggesting that the alternative
splicing of these two isoforms can be regulated (57).
While the significance of this is unclear, the presence or
absence of a stalk does not seem to have significant effects
on the ability of this receptor to recognize b-glucans.
The other isoforms represent a minor population of the
splice variants, and they may serve regulatory roles,
a phenomenon described for other cell surface receptors
such as CD40 (59) and scavenger receptor type A (60).
In addition to its ability to recognize glucans, the
human b-glucan receptor also recognizes a subset of
T cells. Given the similarity of the b-glucan receptors to
those of the NK-cell-like C-type lectin-like domains
(53,61) which normally recognize specific major histo-
compatibility complex class I molecules on target cells,
it is possible that the ligands on T cells are major
histocompatibility complex class I molecules. The ability
of the human b-glucan receptor to recognize only one of
the four T cell lines tested suggests that the ligand is
restricted to a subset of T cells and we are currently
exploring this possibility further (57). While the biological
function of this interaction is unknown at present,
it poses an intriguing role for this receptor in the
recognition of self and non-self ligands (58).
Gastrointestinal Absorption of b-Glucans
There are also reports that some mushroom b-1,3;1,6-glucans
could mediate tumor regression when given orally (62,63).
In more recent studies using human tumor xenografts,
orally administered soluble barley b-1,3;1,4-glucan or
8 The medicinal mushroom Agaricus blazei Murrilli.v. antitumor monoclonal antibodies were ineffective as
single agents, but when combined, elicited a substantial
antitumoreffect(64,65).However,themechanismbywhich
large b-1,3-glucans could be taken up orally by the
gastrointestinal tract and function to prime leukocyte
CR3 was unknown.
Opsonizing Activity of b-1,3-Glucan
An important investigation showed that these large
b-1,3-glucans were taken up by gastrointestinal macro-
phages and shuttled to reticuloendothelial tissues and
bone marrow. Within the marrow, the macrophages
degraded the b-1,3-glucan and secreted small soluble
biologically active fragments that bound to CR3 of
mature bone marrow granulocytes. Once recruited from
the bone marrow by an inflammatory stimulus, these
granulocytes with b-1,3-glucan-primed CR3 could kill
iC3b-coated tumor cells. As had been found earlier
with i.v. soluble yeast b-1,3;1,6-glucan therapy, oral
b-1,3-glucan-mediated tumor regression required the
presence of iC3b on tumors and CR3 on granulocytes,
and therefore failed in mice deficient in C3 or CR3.
Yan (65) showed that the tumoricidal activity of
soluble CR3-binding polysaccharides such as b-glucan
was specific for neoplastic cells that had been
opsonized with C3 through the action of naturally
occurring tumor-reactive antibodies. Tumors that bore a
sufficient density of C3 for recognition by the CR3 of
circulating leukocytes responded to therapy with b-
glucans, whereas tumors that were not opsonized with
C3 did not respond to therapy (66). It is well known
that b-glucan responses occur only in certain strains of
mice bearing specific tumors, so this report (66) suggests
that reports of the sensitivity or resistance of specific
tumors to b-glucan corresponds to the presence or
absence of antibodies capable of opsonizing the tumor
with iC3b, opening new possible therapeutic options for
treatment of immune-based therapies for human cancer.
b-glucans can potentially be used to generate a novel
cell-mediated effector mechanism for tumor vaccines and
antibodies to tumor antigens that otherwise rely mostly
on the direct cytotoxic action of chemotherapy. This
therapy appears to have the greatest applicability to
metastatic tumors that have lost MHC class I and thus
have escaped recognition cytotoxic lymphocytes (66,67).
Such metastatic tumors frequently express polysaccharide
or ganglioside tumor antigens for which there is an array
of available vaccines and antibodies.
Studies in Animals
ABM Extracts as Anticancer Agents
Aqueous extracts of ABM given in the drinking water to
rats and mice before chemical cancer induction exhibited
antimutagenic effects, but were ineffective when adminis-
tered in the post-induction period demonstrating protec-
tion only in the initiation step of liver carcinogenesis
(37,68,69). These studies are of particular interest because
the extraction consisted in preparing a ‘crude aqueous
extract’ leaving a powdered dry fruiting body in water
at room temperature for 2h, which is the way ABM is
popularly prepared (69).
Interestingly, rats fed with a dry powdered form of
ABM using two strains (99/26 and 99/29) and prepared
from two different moments of harvest (opened or closed
basidiocarp) at 10% of the diet, on the basis of the
strain and harvest (the more effective was strain Ab 26
closed basidiocarp) exhibited different significant anti-
mutagenic activity, more evident when considering the
reduction of both size and number of the preneoplastic
lesions, even when given in the post-initiation period (70).
Moreover, not only polysaccharides but also the lipid
fraction of ABM was found to contain a compound with
antitumor activity, subsequently identified as ergosterol
(a precursor of ergocalciferol), that inhibited tumor-
induced neovascularization in sarcoma 180-bearing mice
by oral administration for 20 days without side effects,
though the extract had no cytotoxic effect in vitro (71).
Kimura (72) has identified from the lipid fraction
sodium pyroglutamate, which has shown not only to
have antiangiogenic (inhibition of von Willebrand Factor
expression in tumors) and antitumor activity in Lewis
lung carcinoma-bearing mice but also an inhibitory effect
on the cancer-induced reduction of immune functions.
Ethanol fractions obtained from hot-water extract of
mycelium or dried fruiting induced TNF-a and IL-8
secretion in rat bone-marrow macrophages. Further
fractionation with increasing ethanol concentrations
resulted in the reduction of this cytokine-inducing ability
in mycelial extracts, but enhanced it in fruiting body
extracts. Whereas mycelial fractions did not induce nitric
oxide production, fractions obtained by precipitation of
fruiting-body extract with high ethanol concentrations
stimulated macrophages to produce significantly higher
levels of nitric oxide than controls (23).
In a mouse model of peritonitis induced by i.p. injection
of fecal stem solutions the pre-challenge oral administra-
tion of an aqueous ABM extract protected mice against
lethal septicemia after fecal peritonitis as demonstrated by
a reduction in bacteremia and increase in survival rate,
which was comparable with the survival of a verum group
to which were administered per os metronidazole and
doxycicline (73); and confirming previous results of the
same group in mice given i.p. infection with the virulent
Streptococcus pneumoniae serotype 6B (74).
ABM Extracts as Immunostimulants
In an interesting article (75), experimenting intradermal
injections of four different ABM extracts (ethanol, water,
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Meth-A tumor model, mice administered with the oxalate
soluble fraction were tumor free after 21 days. In the
same article, oral ad lib administration of the same
fraction had no antitumor effect but enhanced that of
the intratumorally injected fraction (P50.01 versus
injection alone) (75). Significant macrophage chemotactic
factor, but not neutrophil chemotactic factor activity,
was detected, while serum levels of immunosuppressive
chemotactic factor (a marker protein of activated
macrophages and neutrophils in response to biological
response modifier) increased dramatically suggesting an
immunopotentiating activity besides a direct cytotoxic
action on tumor cells (75).
The oxalate soluble fraction consisted of a large
amount of carbohydrates (exclusively glucose as deter-
mined by HPLC) and small amounts of proteins;
carbohydrates containing (1-4)-b-D-glucan and (1-6)-b-D-
glucan in the ratio of approximately 1:2 (45,75).
Treatment with hot-water extracts of ABM fruiting
bodies increased NK activity of spleen cells in naive
BALB/c mice (75). In Meth A-bearing BALB/c mice, the
same extracts enhanced the induction of antigen-specific
cytotoxic T-lymphocytes and IFN-g production.
Up-regulation of NK and TC activity was triggered by
IL-12 dependent activation (76) although it is not yet
clear whether oral administration of ABM extract
enhances IL-12 production in vivo (77).
These data are confirmed by a study of Itoh (78) showing
moderate antiblastic activity in mice Meth-A tumor model
but only by i.p. administration of FIII-2-b fraction,
confirmed in another study where a new polysaccharide–
protein complex (called ATOM: antitumor organic sub-
stance Mie) administered p.o. and i.p. appeared highly
active against in mice sarcoma 180, Ehrlich ascites
carcinoma, Shionogi carcinoma 42 and Meth A fibrosar-
coma models, trough activation of immunostimulatory
activity mediated by macrophage and complement (79).
Ehrlich carcinoma-bearing mice treated per os with the
n-hexane (mainly unsaturated fatty acids), dichloro-
methane (sugar and amino acids), or methanol (mainly
unidentified polymers) extracts from ABM fruiting bodies
were able to maintain the NK activity of spleen cells
during the first 10 days after tumor implantation (80).
NK activity in these groups was similar to that of normal
controls and higher than that of tumor-bearing mice
treated with water. After 30 days, animals treated with
n-hexane extract showed lower tumor growth than the
other groups, but mice assuming dichloromethane extract
presented signs of presumed toxicity (necrotic lesions in
the extremity of the tail probably due to residues of
organic solvents). The dichloromethane and methanol
groups produced a more intense humoral response than
the n-hexane and ethanol extract groups.
The results of NK activity on the 30th day after the
injection of tumor cells suggest that none of the three
extracts was able to maintain the lytic activity against
Yac-1 target cells. And 30 days later, the Ehrlich
carcinoma cells were enough to decrease the NK activity,
perhaps, by the production of soluble factors like
prostaglandins, TGF-b, or IL-10 (62).
Tumoricidal Acivity of b-Glucan
In a mouse model, for the first time in 2005, Kobayashi (81)
has demonstrated that daily oral supplementation of
b-glucan by a hydrochloric acid fraction (16.6% proteins,
90% glucose composed by 1-4-a-D-glucan and 1-6-b-D-
glucan in the ratio 1:2) (82) seems the only orally active
preparation in mice with respect to aqueous ammonium
oxalate-soluble and ethanol-insoluble derivatives of ABM
that are active only if administered intratumorally (83),
probably due to a direct effect on tumor invasion and
metastasis through a direct modulation of signalling
cascades: inhibition of thymidine incorporation in a dose-
dependent fashion in ovarian cancer cells in vitro although
not in Lewis lung cancer cells. Data in vitro have been
confirmed in a mouse model of peritoneally disseminated
metastasis of human ovarian cancer by intraperitoneal
injection and confirmed by oral administration, without
influence on mean body weight or food consumption and
the average number of formation of pulmonary nodules
was lower on experimental lung metastasis of Lewis lung
cancer (81). These actions are probably due to the
suppression of cell proliferation, apoptosis and inhibition
of urokinase-type plasminogen activator through promo-
tion of p38 MAPK activation (81).
In reference to other popular supposed pharmacologi-
cal activities, the only experimental data are those
from a model (84) of rats with a streptozocin
induced diabetes treated by oral administration of a
dried fruiting body hot-water extracts showed anti-
hyperglycemic, anti-hypertriglyceridemic, anti-hypercho-
lesterolemic and anti-arteriosclerosis activity indicating
overall anti-diabetic activity in diabetic rats, but oligo-
saccharides obtained by hydrolization of b-glucans by
means of Bacillus megaterium showed higher activity than
b-glucans.
So, many studies show in animals the potential activity
of ABM extracts, and more than a direct antiblastic
activity. Moreover on the basis of in vitro studies it is
possible to assume that the most promising pharmacolog-
ical activities are immunostimulatory and antiangiogenic
probably by means of different extracts (Table 2).
Clinical Studies
ABM in Cancer Patients
According to reports, 100000–300000kg of the dried
body of ABM is produced every year in Japan, and
10 The medicinal mushroom Agaricus blazei Murrillabout 300000–500000 persons for the prevention or
treatment of cancer assume the 3–5g three times a day by
a typical hot-water extract (71). In a small survey on the
use of complementary therapies by patients affected by
urological cancer in Japan, on a total of 293 patients
surveyed, 52 were assuming ABM extracts representing a
percentage of 31% and being the most commonly used
‘health food’ (85). Ahn (86) investigated the beneficial
effects of the oral daily assumption of an extract of
Agaricus blazei Murrill Kyowa (in the exact content and
quantity of substances assumed by patients, and drop out
for any cause were not described in the study) on
immunological status and qualities of life in cancer
patients undergoing chemotherapy. They observed that
NK-cell cytotoxic activity, was significantly higher after a
6 weeks period compared with placebo, although there
was no difference in white blood cells decrease in patients
upon chemotherapy (carboplatin, etoposide and taxol).
However, chemotherapy-associated side effects such as
appetite, alopecia, emotional stability and general weak-
ness were all improved on the base of the QLQ-30
Scoring Manual 2nd edition of EORTC modified by
authors (86).
Clinical Studies in the Treatment of Hypertension,
Hypercholesterolemia and Hepatic diseases
Administration of g-aminobutyric acid (GABA)-enriched
A. blazei (AG-GABA) to mild hypertensive human
subjects, in an open test and double blind cross-over
test, showed that during AG-GABA intake period, both
systolic and diastolic blood pressure values decreased to
statistically significant levels, if compared with those of
the pretest period or placebo intake period. No sig-
nificant difference was observed, neither in the values of
cholesterol nor of hepatic transaminases and g-GTP (87).
The effects of protein-bound polysaccharides (A-PBP
and L-PBP) that were extracted from the mycelia of
A. blazei on serum cholesterol and body weight were
investigated in 90 female volunteers for 8 weeks: the
weight-reduction effect (11.8%) and hypocholesterolemic
effect (11.0%) was most significant, indicating their
synergistic action. These data suggested that the weight-
controlling and hypolipidemic effect of L-PBP and
A-PBP protein-bound polysaccharides were involved, at
least in part, in absorption of cholesterol as their role of
dietary fiber, as well as cholesterol metabolism (88).
A study evaluated the clinical effects and safety on
human volunteers with elevated g-GTP activity of A.
blazei Condensed Liquid (Agaricus Mushroom Extract;
ABCL) in the treatment of C-hepatitis. A total of 20
patients (50% of men) with chronic C-type hepatitis
received the ABCL orally, twice a day, for 8 weeks.
Decreasing effect for serum g-GTP activity was found in
80% of the patients in both sexes; without any
toxicological findings and other side effects (89). These
initial clinical data (Table 3) are interesting, but we think
it is soon to establish definitely a real benefit from the
assumption of ABM extracts although it is not known
exactly which are the active substances, although actually
only b-glucans can be considered as the more active
substance.
Toxicity
The Problem of Heavy Metals and Radioactive Substances
An important clinical-toxicological concern represented
by mushrooms, especially wild ones, is the possible
contamination with substantial levels of toxic metals
such as arsenic, lead, cadmium and mercury as well as
137Cs, because many mushrooms species have the ability
to accumulate radioactive substances such as relatively
high concentrations of metals (90). So high levels of
toxic compounds may offset whatever health benefits
a diet rich in mushrooms or their extract could
potentially confer (88,91,92,93).
Pharmacological Interferences
ABM extract can also down-regulate the expression of
cytochrome P4501A and can be useful in reducing the
production of metabolically activated procarcinogen from
xenobiotics. It can consequently prolong the duration
and intensity of drugs’ activity, and could give rise to
unpredictable side effects or adverse drug reactions (94).
Toxicity in Animals
In a study to evaluate 90-day subchronic toxicity of an
aqueous extract in F344 rats, there were no consistent
Table 2. Main active anticancerogenic substances
Ergosterol Antiangiogenic (71)
Pyroglutamate Antiangiogenic, antiblastic,
(immunostimulant?) (72)
Polysaccharides(1-6)-b-backbone Immunostimulant, (antiblastic?)
(81–83)
Lignin derivatives Immunostimulant (TNF,IL8)
(antiblastic?) (27,29)
Polysaccharide–protein complex immunostimulant, (antiblastic?)
(15,78,79)
Table 3. Clinical studies
Gynecological patients (86) Improvement of quality of life
and immunitary status
Hypertension (87) Lowering of diastolic and systolic
blood pressure
Hypercholesterolemia
and obesity (88)
Hypocholesterolemic and antiobesity
activity
C-type hepatitis (89) Lowering of g-GTP
eCAM 2008;5(1) 11treatment-related changes in clinical signs, body weight
and food consumption at the dose of 2654mgkg
 1 b.w.
day
 1 for male and 2965mgkg
 1 b.w. day
 1 for female
rats, although there was an increase of blood urea
nitrogen in males that was considered unlikely to be of
toxicological significance (contemporary decrease of crea-
tinine and no histopathological changes reported) (95).
Although it has not been established the direct quantity
toxic or cancerogenic for humans, a main problem for the
administration of ABM remains the problem of aromatic
hydrazines (i.e. agaritine and its derivatives) whose
cancerogenicity and chronic systemic effects are well
known in animals for many years (96); probably due to
metabolized toxic intermediates capable of damaging
cellular macromolecules and stimulating proteolysis
giving rise to hydrazine-mediated DNA strand scissions
(97). Toth demonstrated that the administration of
hydrazine analogs administered s.c. in Swiss mice induced
fibrosarcoma in 24% of males, and in both sexes soft
tissue tumors (98); while in another article agaritine
administered in drinking water at 0.062 and 0.031% did
not give rise to cancer although a substantial number of
animals (Swiss mice) developed convulsive seizures (99);
while hydrazine analogs (from A. bisporus and Gyromitra
esculenta) administered in drinking water in Swiss mice
and Syrian hamsters gave rise to liver neoplasms (benign
hepatomas, liver cell carcinomas, angiomas, angiosarco-
mas) and adenomas and adenocarcinomas of lungs (100).
Hydrazines in general have also been found potent
irreversible inactivators of some hemoproteins (101).
Although the stability of the molecule was examined
and that agaritine degrades within 48h in tap water and
that degradation appeared to be oxygen-dependent (102),
the presence in plasma from agaritine-administration in
mice or rats as its definite toxicity remains unclear (103).
The concentration of agaritine in methanol extracts of
food was 112–1836mgg
 1dry weight, in a commercial
product of ABM arrived at 1791gg
 1dry weight and the
calculated one-day intake of the product was estimated to
be 8955g according to the label (104). For this reason the
Ministry of Health, Labour and Welfare of Japan
demanded a cessation of sales and voluntary recall of
the product from K-Company after a request to the Food
Safety Commission to assess the safety of products
containing ABM. Nevertheless, in a clinical test pla-
cebo-controlled to verify human toxicity of ‘Freezing
dryness A. blazei (Iwade strain 101) Himematsutake’,
after 16 weeks, there were no clinical problems in the
blood examination, urinalysis, physical examination and
history taking (105).
Toxicity in Humans
Three cases of severe hepatic dysfunction in cancer
patients have been reported recently. These are prelimin-
ary data, although one patient underwent rechallenge
with the same extract that resulted in deterioration of
liver function again (106). Nevertheless, other causes
cannot be ruled out: there is an apparent probable
relationship between ABM extract and liver damage that
deserves full attention due to the large assumption of the
mushroom as OTC remedy.
Conclusions
Careful clinical studies comparing the activity of isolated
compounds, whole mushroom extracts and epidemiolog-
ical data are still necessary to determine whether ABM
provide real clinical benefits. Dose-response studies and
isolation, as well as chemical identification and quanti-
fication of specific compounds responsible for the
potential benefit from ABM mushroom ingestion
should be fully developed, although there seems to be
clear evidence that ABM extracts are rich in b-glucans
that presumably contribute to the observed immunosti-
mulatory activity.
Other substances are probably involved as well, the
immunostimulation following ingestion of polysacchar-
ides is possible and probably useful in cancer patients
if it does not give rise to pharmacological interferences.
A main safety concern is represented by the toxicity and
cancerogenicity of agaritine and its derivatives that
should be completely evaluated; and probably would be
useful for these mushrooms like other herbal remedies,
to completely define the problem of heavy metal
contents. Due to the large consumption of ABM in
popular medicine, probably more data are needed on
action mechanisms of its component and safety before
counseling the assumption for prevention and treatment
of cancer and immunodepressive disorders.
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